60 related articles for article (PubMed ID: 17623836)
1. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
2. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P; Perkins EB; Honeycut C; Wellons MD; Stefan T; Jacobberger JW; Kontopodis E; Beumer JH; Egorin MJ; Imamura CK; Douglas Figg W; Karp JE; Koc ON; Cooper BW; Luger SM; Colevas AD; Roberts JD; Grant S
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1657-67. PubMed ID: 22349810
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Jabbour E; Kantarjian HM; Jones D; Shan J; O'Brien S; Reddy N; Wierda WG; Faderl S; Garcia-Manero G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Mar; 113(10):2154-60. PubMed ID: 19060245
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
Wetzler M; Donohue KA; Odenike OM; Feldman EJ; Hurd DD; Stone RM; Westerfelt P; Bloomfield CD; Larson RA
Leuk Lymphoma; 2008 Jul; 49(7):1274-8. PubMed ID: 18452072
[TBL] [Abstract][Full Text] [Related]
6. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Dugan E; Truax R; Meadows KL; Nixon AB; Petros WP; Favaro J; Fernando NH; Morse MA; Blobe GC; Hurwitz HI
Anticancer Res; 2010 Apr; 30(4):1251-6. PubMed ID: 20530436
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Gambacorti-Passerini C; Kantarjian HM; Kim DW; Khoury HJ; Turkina AG; Brümmendorf TH; Matczak E; Bardy-Bouxin N; Shapiro M; Turnbull K; Leip E; Cortes JE
Am J Hematol; 2015 Sep; 90(9):755-68. PubMed ID: 26040495
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Santos FP; Kantarjian H; McConkey D; O'Brien S; Faderl S; Borthakur G; Ferrajoli A; Wright J; Cortes J
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):355-60. PubMed ID: 21816374
[TBL] [Abstract][Full Text] [Related]
9. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J; Koh Y; Yoon SH; Cho JY; Kim DY; Lee KH; Kim HJ; Ahn JS; Kim YK; Park J; Sohn SK; Moon JH; Lee YJ; Yoon S; Lee JO; Cheong JW; Kim KH; Kim SH; Kim HG; Kim H; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Shin DY; Oh D; Kim MK; Jung CW; Park S; Kim I
Cancer Med; 2018 May; 7(5):1814-1823. PubMed ID: 29577674
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
Ryan CW; Vuky J; Chan JS; Chen Z; Beer TM; Nauman D
Invest New Drugs; 2011 Apr; 29(2):374-9. PubMed ID: 20012337
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of Vitamin D
Bandyopadhyay A; Palepu S; Dhamija P; Nath UK; Chetia R; Bakliwal A; Vaniyath S; Chattopadhyay D; Handu S
BMJ Open; 2023 Aug; 13(8):e066361. PubMed ID: 37643857
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
Pollack IF; Jakacki RI; Blaney SM; Hancock ML; Kieran MW; Phillips P; Kun LE; Friedman H; Packer R; Banerjee A; Geyer JR; Goldman S; Poussaint TY; Krasin MJ; Wang Y; Hayes M; Murgo A; Weiner S; Boyett JM
Neuro Oncol; 2007 Apr; 9(2):145-60. PubMed ID: 17293590
[TBL] [Abstract][Full Text] [Related]
13. Clinical Activity of TGF-β Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study.
Ahn JH; Lee J; Park C; Beom SH; Kim SH; Lee YH; Yun KH; Kim JE; Baek W; Han YD; Kim SK; Ryu HJ; Jung I; Lee J; Yoon HI; Kim HS
Clin Cancer Res; 2024 Apr; 30(8):1457-1465. PubMed ID: 38363333
[TBL] [Abstract][Full Text] [Related]
14. Changing therapy from Glivecto a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports.
Asfour IA; Elshazly SA
Cases J; 2009 Dec; 2():9342. PubMed ID: 20062598
[TBL] [Abstract][Full Text] [Related]
15. Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline.
Osorio S; Escudero-Vilaplana V; Reguilón-Gallego L; Gómez-Centurión I; Díez JL; Ferrer-Marín F
J Oncol Pharm Pract; 2017 Jan; ():1078155217735689. PubMed ID: 29065786
[TBL] [Abstract][Full Text] [Related]
16. The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad.
Shah SA
Indian J Med Paediatr Oncol; 2013 Jul; 34(3):189-92. PubMed ID: 24516307
[TBL] [Abstract][Full Text] [Related]
17. Lonafarnib-A new member of the Delta Force?
Dietz CA; Cornberg M
Hepatology; 2022 Jun; 75(6):1370-1372. PubMed ID: 35229339
[No Abstract] [Full Text] [Related]
18. Potential Approaches
Andretta E; Costa C; Longobardi C; Damiano S; Giordano A; Pagnini F; Montagnaro S; Quintiliani M; Lauritano C; Ciarcia R
Front Oncol; 2021; 11():801779. PubMed ID: 34993151
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
